Harnessing heterogeneity to treat cancer patients

Cancer is no longer seen as a simple disease of unchecked cell growth, but as a complex, adaptive ecosystem shaped by genetic mutations, immune evasion, and transcriptional plasticity that allow tumours to survive and evolve.

Steve Pollard, CSO & Founder of Trogenix and Professor of Stem Cell and Cancer Biology, University of Edinburgh’s Institute for Regeneration and Repair, outlines this evolution from genetic disease to complex systemic condition.